Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Jan 11, 2018 7:00am EST

Can-Fite 12 Months' Activities & Milestones for 2018

Jan 08, 2018 7:40am EST

Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings

Jan 03, 2018 7:00am EST

Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH

Dec 18, 2017 7:00am EST

Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson

Nov 27, 2017 7:30am EST

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Nov 27, 2017 7:00am EST

Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson

Nov 17, 2017 7:00am EST

Can-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma

Oct 30, 2017 9:50am EDT

Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis

Oct 17, 2017 7:00am EDT

Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis

Oct 16, 2017 7:00am EDT

Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.

  • arrow_back
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding